Goldman Sachs Group Inc. Sells 1,058 Shares of Chemed Co. (NYSE:CHE)

Goldman Sachs Group Inc. reduced its stake in Chemed Co. (NYSE:CHE) by 1.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 53,298 shares of the company’s stock after selling 1,058 shares during the quarter. Goldman Sachs Group Inc. owned about 0.35% of Chemed worth $31,166,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently made changes to their positions in CHE. Kestra Advisory Services LLC grew its position in shares of Chemed by 3.8% during the 3rd quarter. Kestra Advisory Services LLC now owns 634 shares of the company’s stock worth $329,000 after purchasing an additional 23 shares in the last quarter. Envestnet Portfolio Solutions Inc. acquired a new position in shares of Chemed during the 3rd quarter worth approximately $639,000. Envestnet Asset Management Inc. grew its position in shares of Chemed by 38.3% during the 3rd quarter. Envestnet Asset Management Inc. now owns 71,431 shares of the company’s stock worth $37,122,000 after purchasing an additional 19,785 shares in the last quarter. FMR LLC grew its position in shares of Chemed by 15.4% during the 3rd quarter. FMR LLC now owns 214,994 shares of the company’s stock worth $111,732,000 after purchasing an additional 28,682 shares in the last quarter. Finally, Invesco Ltd. grew its position in shares of Chemed by 10.6% during the 3rd quarter. Invesco Ltd. now owns 115,139 shares of the company’s stock worth $59,838,000 after purchasing an additional 10,990 shares in the last quarter. Institutional investors and hedge funds own 95.85% of the company’s stock.

Wall Street Analysts Forecast Growth

CHE has been the topic of a number of analyst reports. Royal Bank of Canada decreased their target price on shares of Chemed from $712.00 to $697.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 21st. Oppenheimer increased their price target on shares of Chemed from $625.00 to $650.00 and gave the stock an “outperform” rating in a research report on Thursday, February 29th. Finally, StockNews.com upgraded shares of Chemed from a “hold” rating to a “buy” rating in a research report on Saturday, May 4th.

Insider Buying and Selling at Chemed

In other Chemed news, EVP Spencer S. Lee sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 28th. The shares were sold at an average price of $641.65, for a total value of $1,283,300.00. Following the sale, the executive vice president now owns 20,760 shares in the company, valued at $13,320,654. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, EVP Spencer S. Lee sold 2,000 shares of the firm’s stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $641.65, for a total transaction of $1,283,300.00. Following the completion of the transaction, the executive vice president now owns 20,760 shares of the company’s stock, valued at $13,320,654. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Patrick P. Grace sold 284 shares of the firm’s stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $540.98, for a total transaction of $153,638.32. Following the transaction, the director now directly owns 3,270 shares of the company’s stock, valued at approximately $1,769,004.60. The disclosure for this sale can be found here. Insiders have sold 7,784 shares of company stock worth $4,523,353 over the last quarter. Corporate insiders own 3.32% of the company’s stock.

Chemed Trading Up 1.7 %

NYSE CHE opened at $542.47 on Friday. The firm has a market capitalization of $8.21 billion, a price-to-earnings ratio of 29.20, a P/E/G ratio of 2.20 and a beta of 0.46. The firm’s 50 day simple moving average is $563.69 and its 200 day simple moving average is $590.17. Chemed Co. has a 1 year low of $492.84 and a 1 year high of $654.62.

Chemed (NYSE:CHE) last issued its earnings results on Wednesday, April 24th. The company reported $4.68 earnings per share for the quarter, missing analysts’ consensus estimates of $5.09 by ($0.41). Chemed had a net margin of 12.36% and a return on equity of 30.52%. The company had revenue of $589.23 million during the quarter, compared to analyst estimates of $587.18 million. On average, equities research analysts forecast that Chemed Co. will post 21.54 earnings per share for the current year.

Chemed Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 18th. Shareholders of record on Thursday, May 30th were given a $0.40 dividend. The ex-dividend date was Thursday, May 30th. This represents a $1.60 dividend on an annualized basis and a yield of 0.29%. Chemed’s dividend payout ratio is currently 8.61%.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.